Related Experiment Video
Updated: Jun 7, 2026
06:10
Extrahepatic Bile Duct and Gall Bladder Dissection in Nine-Day-Old Mouse Neonates
Published on: August 23, 2022
Trafficking and transporter disorders in pediatric cholestasis
1Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, UK. alex.knisely@kcl.ac.uk
Clinics in Liver Disease
|November 9, 2010
Summary
Immunostaining aids in diagnosing pediatric cholestasis by identifying specific protein deficiencies. This helps pinpoint genetic causes, guiding targeted sequencing for conditions like ABCB11 and ABCB4 mutations.
Area of Science:
- Hepatology
- Medical Diagnostics
- Genetics
Background:
- Cholestasis, particularly severe forms presenting early in life, poses diagnostic challenges.
- Accurate diagnosis is crucial for timely genetic counseling and potential therapeutic interventions.
Purpose of the Study:
- To elucidate the utility of immunostaining techniques in the etiological diagnosis of cholestasis.
- To correlate specific protein expression patterns with likely genetic mutations in hepatobiliary diseases.
Main Methods:
- Immunostaining for bile salt export pump (BSEP) and multidrug resistance protein 3 (MRP3).
- Immunostaining for canalicular ectoenzymes and transporters, complemented by transmission electron microscopy.
- Utilizing immunostaining for multidrug resistance-associated protein 2 (MRP2) as a processing control.
Main Results:
- Immunostaining for BSEP and MRP3 can rapidly suggest the likelihood of mutations in ABCB11 or ABCB4.
- Combined immunostaining and electron microscopy can indicate the probability of ATP8B1 mutations.
- Absence of BSEP expression may point towards bile acid synthesis disorders.
Conclusions:
- Immunostaining is a valuable tool for the rapid etiological diagnosis of cholestasis.
- This approach effectively directs genetic sequencing efforts, optimizing diagnostic yield for inherited hepatobiliary disorders.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:14Hepatic Drug Clearance: Role of Transporters
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
01:31ABC Transporters: Exporter
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...